These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 709565)

  • 1. Monitoring of anthracycline cardiotoxicity.
    Bristow MR; Mason JW; Daniels JR
    Cancer Treat Rep; 1978 Oct; 62(10):1607-8. PubMed ID: 709565
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection.
    Mortensen SA; Aabo K; Jonsson T; Baandrup U
    Int J Clin Pharmacol Res; 1986; 6(2):137-50. PubMed ID: 3459718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing the cardiotoxicity of the anthracyclines.
    Carlson RW
    Oncology (Williston Park); 1992 Jun; 6(6):95-100, 104, 107, discussion 107-8. PubMed ID: 1535212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective monitoring for anthracycline cardiotoxicity: an introduction.
    McGuire WP
    Cancer Treat Rep; 1978 Jun; 62(6):855. PubMed ID: 667858
    [No Abstract]   [Full Text] [Related]  

  • 5. The endomyocardial biopsy.
    Schneiderman H; Hager WD; Gondos B
    Ann Clin Lab Sci; 1986; 16(2):134-45. PubMed ID: 3516054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the myocardial biopsy to monitor cardiotoxicity.
    Billingham M
    Cancer Treat Rep; 1978 Oct; 62(10):1607. PubMed ID: 709564
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anthracycline-induced cardiotoxicity: monitoring and prevention of the lesion].
    Orditura M; De Vita F; Ciaramella F; Catalano G
    Ann Ital Med Int; 1994; 9(4):243-8. PubMed ID: 7893575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of cardiac pathology in relation to anthracycline cardiotoxicity.
    Ferrans VJ
    Cancer Treat Rep; 1978 Jun; 62(6):955-61. PubMed ID: 352510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.
    Steinherz LJ; Graham T; Hurwitz R; Sondheimer HM; Schwartz RG; Shaffer EM; Sandor G; Benson L; Williams R
    Pediatrics; 1992 May; 89(5 Pt 1):942-9. PubMed ID: 1579408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline cardiotoxicity: new insights.
    Mushlin PS; Olson RD
    Ration Drug Ther; 1988 Dec; 22(12):1-9. PubMed ID: 3256005
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anthracycline cardiotoxicity: review].
    Ribera JM; Montserrat E; Rozman C
    Sangre (Barc); 1983; 28(1):54-68. PubMed ID: 6346540
    [No Abstract]   [Full Text] [Related]  

  • 14. Endomyocardial biopsy.
    Laser JA; Fowles RE; Mason JW
    Cardiovasc Clin; 1985; 15(1):141-63. PubMed ID: 3916087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiologic sequelae of cytostatic therapy].
    Mladosievivcová B
    Cas Lek Cesk; 2001 Mar; 140(5):138-41. PubMed ID: 11347200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline associated cardiac toxicity in children with malignancies.
    Mohta R; Saxena A; Jain Y; Gupta S; Thavaraj V; Narain S; Arya LS
    Indian Pediatr; 2002 Jun; 39(6):549-55. PubMed ID: 12084948
    [No Abstract]   [Full Text] [Related]  

  • 18. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
    van Dalen EC; van den Brug M; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
    Menna P; Recalcati S; Cairo G; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac toxicity of adriamycin-DNA complex and rubidazone: evaluation by electrocardiogram and endomyocardial biopsy.
    Benjamin RS; Mason JW; Billingham ME
    Cancer Treat Rep; 1978 Jun; 62(6):935-9. PubMed ID: 667871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.